Need help?

800-5315-2751 Hours: 8am-5pm PST M-Th;  8am-4pm PST Fri
Medicine Lakex

The DoseMe® Platform Personalised Medicine: Making Complex Simple What is DoseMe®?DoseMe is an easy-to-use Bayesian dose-individualisation platform designed for clinicians and healthcare practitioners to optimise patient care. DoseMe currently supports several classes of drugs, including antibiotics, anti-coagulants, and chemotherapeutic agents. DoseMe supports label or guideline-based dosing as well as dose-individualisation.
Why Dose-Individualise?Adverse drug events on average require 4.6 additional hospital days, at a cost of approximately $10,000.1 For the commonly used antibiotic, gentamicin (which makes up approximately 7% of total hospital antibiotic use2), the effects of adverse dosing events include nephrotoxicity and vestibular damage. These each occur in conservatively 2-3% of patients, but likely significantly more.3,4 For large tertiary hospitals, conservatively assuming 2-3%, this is approximately $3 million per annum for each hospital, just for gentamicin. In fact, other drugs such as warfarin have substantially higher adverse drug Appropriate methods of dose adjustment and individualisation have been shown to reduce adverse drug events by 75-80%.5 Furthermore, Bayesian dose individualisation has been shown to significantly extend life for patients undergoing Finally, computerised dose individualisation has been mandated by the 2010 Australian Therapeutic Guidelines for the use of aminoglycosides. Gentamicin toxicity is a known issue to the legal community, with some law firms specialising in these Drug SupportDoseMe currently supports the following drugs: • Amikacin (adults and paediatric) • Itraconazole (adults and paediatric) • Busulfan (adults and paediatric) • Methotrexate (adults and paediatric) • Ciclosporin (adults) (adults and paediatric) • Enoxaparin (adults) • Tobramycin (adults and paediatric) • Gentamicin (adults and paediatric) • Vancomycin (adults and paediatric) • Factor VIII (adults and paediatric) • Voriconazole (adults) • Flucloxacillin (adults and paediatric) (adults and paediatric) New drugs are being added continually, and DoseMe can support specific drugs on request. DoseMe does not limit the number of compartments or the types and kinds of covariates supported in drug models.
Clinically TestedDoseMe has undergone multiple trials for both accuracy and usability. DoseMe was found in a recent study to be the most accurate individualised dosing method tested, having both the lowest bias and highest precision.9 These trials report extremely positive findings, both for clinical outcomes, and DoseMe's ease-of-use. DoseMe was initially developed in conjunction with clinical and research staff in the Royal Brisbane and Womens' Hospital – the largest teaching hospital in the southern hemisphere – for both clinical and research purposes. DoseMe has been piloted at multiple hos- pitals across Australia and Eur These programmes [iPad and web-interface] provide easy to use dosing "support for these difficult to dose medications… We have found the DoseMe software very straightforward for doctors to use. " - Professor and Clinical Pharmacologist, Brisbane Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997;277(4):307-11.
CHRISP. Antimicrobial Utilisation Report to Queensland Health Medicines Advisory Committee. May 2012.
Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13(1):119-26. Review.
Selby NM, Shaw S, Woodier N, Fluck RJ, Kolhe NV. Gentamicin-associated acute kidney injury. QJM. 2009 Dec;102(12):873-80.
Executive summary of disease management of drug hypersensitivity: a practice parameter. Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 1999;83:665-700 Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998 Feb 19;338(8):499-505 Keith S. Douglass & Associates, L.L.P. Oshman & Mirisola, LLP. Hennig S, Stiller F, Teo B, Staatz C. Comparing methods for once daily tobramycin exposure predictions in children with cystic fibrosis. PAGANZ 2014.
Designed for the ClinicDoseMe has been designed from the ground-up to seamlessly fit into a clinical workflow. DoseMe supports use by the bedside (iPads / iPhones), the desktop (web interface), as well as integrating into existing patient management software.
(Cloud or Physical) DoseMe supports industry standard integration languages, including HL7, and is currently being extended to provide dosing recommendations (after physician approval) to patient phones.
Custom integration services are also available to suit whatever clinical requirements you may have.
Schematic of DoseMe's logical architecture.
Fully SupportedDoseMe is a fully-supported product 24x7, with both phone and online support. DoseMe has partnered with a leading global IT solution provider, allowing DoseMe to provide world-wide support, localisation, and implementation services.
Performance and availability of the DoseMe Platform is continually monitored, so you can rely on DoseMe being there when you need it.
A Regulated Medical DeviceDosing support software is considered a regulated medical device in much of the world. DoseMe has obtained CE marking, TGA approval, and hopes to shortly file for FDA approval. Designed and built to comply with these requirements from the beginning, DoseMe gives you confidence that you're using software developed and maintained to the rigorous standards appropriate for a clinical Every time a new DoseMe installation occurs, or an update is prepared for release, a large set of validation tests (thousands) are automatically performed to ensure that DoseMe remains numerically precise. Before releasing updates, user acceptance testing of DoseMe is also undertaken – making sure DoseMe's interface is suitable for clinical practice.
Every model incorporated in DoseMe goes through rigorous review by an expert pharmacometrician.
Cloud-Based and ScalableDoseMe is a cloud-based solution that can be deployed and made available immediately, without requiring lengthy and difficult IT compatibility projects. However, we do support integration with in-house systems if required. DoseMe scales seamlessly, supporting 1 to more than 100,000 patients.
Safe & SecureDoseMe Pty Ltd is committed to safe and secure data storage and transmission. • DoseMe encrypts all communication using bank-grade • We comply with data security and privacy legislation. Our privacy policy is available on our website.
• All servers used by a given clinic are hosted in the same jurisdiction, simplifying your legal requirements.
For More InformationTo learn more about DoseMe, please feel free to contact the DoseMe team with any questions or for a demonstration. In the past, DoseMe has presented to specific clinical units (e.g. renal units), mixed-speciality audiences (e.g. grand rounds), as well as to research and management DoseMe evaluation accounts are available free on request. Send us an email or give us a call to get started with personalised medicine today.
T +61 7 3151 3033 M +61 421 979 896 Copyright 2015 DoseMe Pty Ltd. All rights reserved. DoseMe is a trademark of DoseMe Pty Ltd. All other trademarks mentioned herein are the sole property of their respective owners.



Your GP or Endocrinologist may also check: What do I need to know about my medication?  Kidney function  The aim of treatment is to abolish symptoms – not  Phosphate and magnesium levels to restore ‘normal' calcium levels in the blood.  Vitamin D levels  In the absence of PTH, higher levels of calcium are found in the urine for a given blood calcium level.

MODELLING THE SPATIAL-TEMPORAL EVOLUTION OF THE 2009 A/H1N1 INFLUENZA PANDEMIC IN CHILE URGERA, GERARDO CHOWELLB, PEP MULETC, AND LUIS M. VILLADAD Abstract. A spatial-temporal transmission model of 2009 A/H1N1 pandemic influenzaacross Chile, a country that spans a large latitudinal gradient, is developed to characterizethe spatial variation in peak timing of the 2009 A/H1N1 influenza as a function of spatialconnectivity assumptions across Chilean regions and the location of introduction of the virusinto the country. The resulting model is a SEIR (susceptible-exposed-infected-removed)compartmental model with local diffusion and optional non-local terms to describe themigration of individuals of the S, E and R classes and the effect of a "hub region". Thismodel is used along with epidemiological data to explore the spatial-temporal progressionof pandemic influenza in Chile by assuming a range of transmission scenarios. Numericalresults indicate that this relatively simple model is sufficient to characterize the south-northgradient observed during the 2009 influenza pandemic in Chile, and that the "hub region"corresponding to the capital region plays the critical role in keeping the population wellmixed in a relatively short period of time.